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Independent data monitoring committee is responsible
for review of the ongoing safety of participants and the
validity and integrity of data in clinical trials and for
making recommendations to the sponsor whether the
trial should continue as planned, be modified or be ter-
minated because of safety concern, futility of the trial,
or treatment benefit. Use of DMCs by government and
industry sponsors has been growing steadily ever since
the announcement by the US National Institutes of
Health in 1998 and by the Food and Drug Administra-
tion in 2001 of policy and guidelines for data and safety
monitoring.
Since a statistical analysis plan serves as a benchmark
for the final analysis and the final report for regulatory
filing, it needs to be explicit about its contents including
the specific statistical analyses to be used. An interim
analysis plan, however, serves as a benchmark for the
ongoing review of the safety and efficacy data by the
DMC and therefore it cannot be codified as in an SAP
as it needs to be flexible to address any concerns raised
by the DMC during the trial and to evolve with the
emerging issues in the monitoring of the study. More
importantly it needs to summarize and present the
interim safety and efficacy data in the most succinct way
to facilitate the review of the ongoing risk-benefit of the
trial and to help the DMC members comprehend the
contents of the report in the most efficient way.
Industry and contract research organization practices
continue to be less than desirable in that there is a ten-
dency to consider the interim analysis plan and resulting
interim reports merely as a subset of the statistical ana-
lysis plan and the final report. This presentation will
offer some thoughts on how the interim report should
be prepared for DMC review and to improve the con-
tents of the interim report.
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